By Keith Loria | Special to Veterinary Practice News

Executive Overview

For decades, a diagnosis of feline infectious peritonitis (FIP) carried an emotional and professional weight that few veterinarians cared to shoulder. Historically viewed as an almost uniformly fatal condition, FIP devastated cat populations worldwide, leaving clinicians with little more than supportive care options and the heart-wrenching task of discussing euthanasia with devoted pet owners.

Today, the landscape of feline medicine has dramatically shifted. The advent of targeted antiviral medications has turned a once-hopeless prognosis into a manageable, and frequently curable, medical reality. However, this therapeutic revolution has exposed a critical vulnerability in modern veterinary practice: the lack of a single, dependable antemortem test capable of universally confirming or excluding FIP in every patient.

This diagnostic uncertainty is no longer just an academic hurdle—it is a race against time. Because effective treatments exist, an accurate and rapid diagnosis directly dictates whether a cat lives or dies. Entering this high-stakes arena is a groundbreaking diagnostic study spearheaded by Colorado State University (CSU). Researchers have evaluated multiplex fluorescent immunocytochemistry (MF-ICC), a novel, minimally invasive assay designed to detect feline coronavirus antigen directly inside macrophages—the primary cells responsible for systemic disease—without requiring risky surgical biopsies.

While researchers emphasize that MF-ICC is not a standalone "silver bullet," its integration into veterinary diagnostics marks a major leap forward. By combining cutting-edge cellular marker technology with a comprehensive clinical puzzle, veterinary medicine is moving closer to the precision required to save lives in an era where every hour counts.

Detailed Chronology & Scientific Evolution

The journey toward reliable FIP diagnostics has been fraught with scientific hurdles. Feline coronavirus (FCoV) is exceptionally common, particularly in multi-cat environments, catteries, and shelters. Yet, the vast majority of cats exposed to the enteric form of the virus never develop FIP. This high background prevalence severely complicates conventional testing methods, which often detect exposure or viral shedding rather than true systemic disease.

Historically, clinicians have relied on a patchwork of tests:

• RT-PCR assays to search for viral RNA.
• Serology to measure a patient’s antibody response to the coronavirus.
• Biochemical changes, such as the serum albumin-to-globulin (A:G) ratio, to support clinical suspicions.
• Histopathology combined with immunohistochemistry (IHC), which remains the gold standard for a definitive diagnosis but typically requires invasive surgical biopsies that unstable or deteriorating patients cannot safely tolerate.

Recognizing the urgent need for a better method, a collaborative team of veterinary pathologists and clinicians—led by Samantha J.M. Evans, DVM, PhD, DACVP, DACVM, associate professor of clinical pathology at CSU—set out to test MF-ICC in cats presenting with clinical signs compatible with FIP.

The Science of MF-ICC: Looking Inside the Right Cell

What sets MF-ICC apart is its precision targeting. Instead of merely identifying the presence of viral RNA or antibodies floating in bodily fluids, MF-ICC uses fluorescent antibodies to detect both the feline coronavirus antigen and vimentin, a vital cellular marker used to identify macrophages.

Macrophages are the central battleground and hallmark cell type of systemic FIP. By capturing images at different wavelengths and superimposing them, laboratory specialists can definitively determine whether both the viral antigen and the cellular marker are present within the same macrophage.

"The innovation we added was multiplexing [the viral marker] with another marker for cellular antigen called vimentin," explains Dr. Evans. "That cellular marker allows us to look specifically at macrophages, which are the hallmark cell type of FIP."

Co-author Benjamin Curtis, DVM, DACVP, clinical assistant professor at the University of Michigan’s Unit for Laboratory Animal Medicine Pathology Core, emphasizes the practical benefits of this dual-staining approach.

"It’s minimally invasive," Dr. Curtis notes. "Pulling fluid out of the belly or doing a needle aspirate is much less invasive than needing to do a tissue biopsy. But then it brings in the gold-standard concept of immunohistochemistry, in that we can confirm there is viral antigen inside the cells that matches the presentation of FIP."

Crucially, sample collection for MF-ICC—which can utilize effusion fluids or fine-needle aspirates from affected tissues—can frequently be performed without subjecting a fragile patient to general anesthesia.

Supporting Context & Metrics: What the Clinical Trial Found

To rigorously evaluate the efficacy of MF-ICC, the research team conducted a comprehensive clinical trial involving 84 cats: 58 confirmed FIP cases and 26 control subjects diagnosed with alternative diseases.

The researchers compared MF-ICC against three established diagnostic approaches: RT-PCR, serology, and the serum albumin-to-globulin ratio. Final case determinations were meticulously established using necropsy findings with histopathology and immunohistochemistry, documented responses to antiviral treatments, and thorough clinical follow-ups.

Performance Breakdown

Using a conservative diagnostic threshold of at least one cell positive for both markers, MF-ICC yielded the following statistical performance metrics within the study cohort:

• Sensitivity: 77 percent
• Specificity: 81 percent
• Positive Predictive Value (PPV): 92 percent
• Negative Predictive Value (NPV): 53 percent
• Overall Accuracy: 78 percent

For comparison, within this specific cohort, overall accuracy stood at 76 percent for the serum albumin-to-globulin ratio, 75 percent for serology, and 69 percent for RT-PCR.

One of the most striking revelations of the study caught Dr. Evans entirely by surprise: the presence of a single dual-positive cell was enough to drive optimal overall accuracy.

"Literally a single virus-infected cell was enough information to discriminate FIP versus non-FIP disease," Dr. Evans remarks. "It was surprising to me that little material was clinically significant."

Nuances Across Disease Presentations

The study also highlighted how assay performance varies depending on the clinical presentation of FIP:

• Effusive ("Wet") FIP: MF-ICC demonstrated higher sensitivity but lower specificity when performed on effusion fluids.
• Non-Effusive ("Dry") FIP: In tissue samples from cats with non-effusive FIP—historically the most difficult form to diagnose—a positive MF-ICC result carried immense diagnostic weight, offering a powerful tool for resolving ambiguous cases.

Furthermore, Dr. Evans warns that the 78 percent overall accuracy figure should not be interpreted as proof that MF-ICC is categorically superior to PCR in every clinical scenario. While substantial for a veterinary trial, the cohort size means small numerical differences must be interpreted with caution.

Perhaps the most valuable takeaway for practicing veterinarians is that MF-ICC and RT-PCR are complementary, not competing, tools.

"MF-ICC picked up some FIP cases that PCR did not, and PCR picked up some FIP cases that MF-ICC did not," Dr. Evans notes. "There is value to ordering both. You’ll have a greater chance of picking up an FIP case by submitting both, and the same sample type can be used for these different assays in a complementary way."

Official Statements & Expert Perspectives

The stakes surrounding FIP diagnosis have skyrocketed in the wake of modern antiviral therapies. No longer merely an academic exercise, diagnostic clarity directly influences financial investment, animal welfare, and therapeutic stewardship.

Dr. Benjamin Curtis underscores the sheer velocity required in clinical settings where severely debilitated cats may only have days—not weeks—left for intervention.

"Having something with a rapid turnaround is going to be life and death for a lot of cats," Dr. Curtis stresses. "Being able to get a rapid answer lets owners and veterinarians know whether we need to start moving on treatment or make other decisions."

This sentiment is echoed by study co-author Petra Černá, PhD, DACVIM (SAIM), Dipl. ECVIM-CA, DABVP (Feline), MANZCVS, an assistant professor of small animal internal medicine at the University of Georgia. Dr. Černá has witnessed firsthand the dangers of misdirected therapy in clinical practice.

"It is very important to have access to fast and accurate diagnostic tests so we can confidently treat these cats," Dr. Černá states. "Very often, I see cases that have been treated for several weeks with antiviral therapy, and they do not have FIP. That is not good antiviral stewardship, but we are also missing the actual diagnosis and are not able to help these patients."

For primary care veterinarians managing complex cases, MF-ICC provides an invaluable safety net. Whether cytology samples have already been drawn, residual material for RT-PCR was lost, or PCR results return negative despite a persistent clinical suspicion of FIP, MF-ICC broadens the diagnostic horizon.

"I think this test is another helpful tool in our toolbox to feel more confident about FIP diagnosis," Dr. Černá adds. "No single test is perfect, and the more possibilities we have, the better we can diagnose these cats and treat them appropriately."

Future Outlook & Next Steps in Feline Medicine

While MF-ICC represents a monumental step forward, it is not currently an in-clinic point-of-care test. It demands specialized laboratory equipment to concentrate cells onto slides, specialized fluorescent reagents, and the trained eye of an expert veterinary pathologist to interpret complex staining patterns.

To bridge the gap between research and clinical application, Colorado State University intends to make the assay commercially available through its Veterinary Diagnostic Laboratory, continuously evaluating its performance as field data accumulates. Dr. Evans envisions MF-ICC serving as a cornerstone within a comprehensive FIP diagnostic service package—combining MF-ICC, RT-PCR, biochemical ratios, and comprehensive patient data.

Concurrently, research teams at CSU are developing advanced machine-learning algorithms utilizing routine complete blood count (CBC) and serum biochemistry findings to assist practitioners. Repositories such as CSU’s FIP biobank and digital archive will further empower retrospective studies as long-term patient outcomes become available.

Importantly, the published methodology behind MF-ICC is not proprietary. Dr. Curtis notes that veterinary diagnostic laboratories equipped with the requisite technology can readily acquire the necessary antibodies and reagents to establish the assay in-house, promising reduced shipping times and faster turnaround for veterinary clinics nationwide.

The Horizon of FIP Research

As survival rates climb, veterinary researchers must pivot toward addressing the uncharted territory of post-treatment health. Dr. Černá points out critical new avenues for investigation:

• Managing critically ill patients presenting with severe systemic inflammation, suspected viral sepsis, immune-mediated hemolytic anemia, myocarditis, or concurrent infections.
• Monitoring long-term outcomes in cats that successfully beat FIP. Emerging clinical observations indicate that some survivors later develop chronic gastrointestinal diseases or large-cell lymphoma—complications that were impossible to study when FIP was universally fatal.

Ultimately, the veterinary community is reminded that diagnosing FIP remains an exercise in clinical synthesis rather than blind reliance on a single laboratory value.

"There’s no perfect test for FIP," Dr. Evans concludes. "One piece is PCR, one is MF-ICC, and this new test is one part of putting together that puzzle."